Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17,377 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Establishment of a novel human CIC-DUX4 sarcoma cell line, Kitra-SRS, with autocrine IGF-1R activation and metastatic potential to the lungs.
Nakai S, Yamada S, Outani H, Nakai T, Yasuda N, Mae H, Imura Y, Wakamatsu T, Tamiya H, Tanaka T, Hamada K, Tani A, Myoui A, Araki N, Ueda T, Yoshikawa H, Takenaka S, Naka N. Nakai S, et al. Among authors: tanaka t. Sci Rep. 2019 Nov 1;9(1):15812. doi: 10.1038/s41598-019-52143-3. Sci Rep. 2019. PMID: 31676869 Free PMC article.
Eribulin Suppresses Clear Cell Sarcoma Growth by Inhibiting Cell Proliferation and Inducing Melanocytic Differentiation Both Directly and Via Vascular Remodeling.
Nakai S, Tamiya H, Imura Y, Nakai T, Yasuda N, Wakamatsu T, Tanaka T, Outani H, Takenaka S, Hamada K, Myoui A, Araki N, Ueda T, Yoshikawa H, Naka N. Nakai S, et al. Among authors: tanaka t. Mol Cancer Ther. 2020 Mar;19(3):742-754. doi: 10.1158/1535-7163.MCT-19-0358. Epub 2019 Dec 3. Mol Cancer Ther. 2020. PMID: 31796507
Author Correction: Establishment of a novel human CIC-DUX4 sarcoma cell line, Kitra-SRS, with autocrine IGF-1R activation and metastatic potential to the lungs.
Nakai S, Yamada S, Outani H, Nakai T, Yasuda N, Mae H, Imura Y, Wakamatsu T, Tamiya H, Tanaka T, Hamada K, Tani A, Myoui A, Araki N, Ueda T, Yoshikawa H, Takenaka S, Naka N. Nakai S, et al. Among authors: tanaka t. Sci Rep. 2020 Jan 15;10(1):684. doi: 10.1038/s41598-019-55752-0. Sci Rep. 2020. PMID: 31941891 Free PMC article.
Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma.
Wakamatsu T, Naka N, Sasagawa S, Tanaka T, Takenaka S, Araki N, Ueda T, Nishizawa Y, Yoshikawa H, Itoh K. Wakamatsu T, et al. Among authors: tanaka t. Cancer Sci. 2014 Sep;105(9):1124-34. doi: 10.1111/cas.12469. Epub 2014 Sep 3. Cancer Sci. 2014. PMID: 24975049 Free PMC article.
Survival analysis of elderly patients with osteosarcoma.
Imura Y, Takenaka S, Kakunaga S, Nakai T, Wakamatsu T, Outani H, Tanaka T, Tamiya H, Oshima K, Hamada K, Naka N, Araki N, Kudawara I, Ueda T, Yoshikawa H. Imura Y, et al. Among authors: tanaka t. Int Orthop. 2019 Jul;43(7):1741-1747. doi: 10.1007/s00264-019-04332-y. Epub 2019 Apr 22. Int Orthop. 2019. PMID: 31011764
17,377 results
You have reached the last available page of results. Please see the User Guide for more information.